On May 14, 2025, Vertex Pharmaceuticals held its annual shareholders meeting, where board members were elected, the accounting firm Ernst & Young LLP was ratified, the 2024 executive compensation program was approved, and a proposal on excessive golden parachutes was rejected. Notably, Sangeeta Bhatia received 224 million votes in favor, while the shareholder proposal on golden parachutes garnered 141 million votes against.